Tanvex BioPharma, Inc. (TPE:6541)
Taiwan
· Delayed Price · Currency is TWD 39.75
-0.45 (-1.12%)
Apr 29, 2026, 1:30 PM CST
Tanvex BioPharma Company Description
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States.
The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.
It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
Tanvex BioPharma, Inc.
| Country | Cayman Islands |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Stephen Lam |
Contact Details
Address: 802 West Bay Road George Town, KY1-1205 Cayman Islands | |
| Website | tanvex.com |
Stock Details
| Ticker Symbol | 6541 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG8676P1037 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stephen Lam | Chief Executive Officer and Director |
| Dr. Allen Y. Chao Ph.D. | Founder and Honorary Chairman |
| James Williamson | Chief Accounting Officer |
| John R. Mosack | Chief Operating Officer of US |
| Miguel Carrion | Vice President of Research & Development - USA |
| Angela Luan | Chief Financial Officer and Corporate Governance Officer |
| Val Chen | Vice President of Finance, Director of Operations. Management and Corporate Governance Officer |
| Zheng Xia | Chief Technology Officer |
| Linda Grillo | Director of Sales and Marketing |
| Marc Goemans | Chief Commercial Officer |